SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Biogen Reports Two-Year Diranersen Data in Early Alzheimer’s Disease

Biogen said Phase 2 CELIA study data show increasing clinical benefit from investigational diranersen in people with early Alzheimer’s disease.

BIIB

Related stories